Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glen T Schumock

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
Pharmacotherapy|March 31, 2012
Cost is not a barrier to implementing clopidogrel pharmacogeneticsLarisa H Cavallari, Glen T Schumock
Pharmacoeconomics|October 2, 2014
Should off-label drugs be included as comparators in pharmacoeconomic studies?Surrey M Walton, Glen T Schumock
The Annals of Pharmacotherapy|July 5, 2007
Need to develop a legal and ethical base for pharmaceutical care. 1994Richard A Hutchinson, Glen T Schumock
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2009
Evaluation and justification of clinical pharmacy servicesScott V Anderson, Glen T Schumock
Pharmacotherapy|December 13, 2016
The Rising Cost of Prescription Drugs: Causes and SolutionsGlen T Schumock, Lee C Vermeulen
Drugs & Aging|May 17, 2003
Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making?Charles L Bennett, Glen T Schumock
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 4, 2009
Comparative effectiveness research: Relevance and applications to pharmacyGlen T Schumock, A Simon Pickard
Journal of Comparative Effectiveness Research|February 22, 2018
Comparative effectiveness and patient-centered outcomes research: enhancing uptake and use by patients, clinicians and payersGlen T Schumock, A Simon Pickard
Healthcare Financial Management : Journal of the Healthcare Financial Management Association|October 17, 2003
Expenditures for prescription drugs: too much or not enough?Glen T Schumock, Surrey M Walton
Archives of Internal Medicine|December 3, 2002
Aspirin use may change cost-effectiveness of COX-2 inhibitorsA Simon Pickard, Glen T Schumock
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
Pharmacotherapy|March 31, 2012
Cost is not a barrier to implementing clopidogrel pharmacogeneticsLarisa H Cavallari, Glen T Schumock
Pharmacoeconomics|October 2, 2014
Should off-label drugs be included as comparators in pharmacoeconomic studies?Surrey M Walton, Glen T Schumock
The Annals of Pharmacotherapy|July 5, 2007
Need to develop a legal and ethical base for pharmaceutical care. 1994Richard A Hutchinson, Glen T Schumock
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2009
Evaluation and justification of clinical pharmacy servicesScott V Anderson, Glen T Schumock
Pharmacotherapy|December 13, 2016
The Rising Cost of Prescription Drugs: Causes and SolutionsGlen T Schumock, Lee C Vermeulen
Drugs & Aging|May 17, 2003
Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making?Charles L Bennett, Glen T Schumock
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 4, 2009
Comparative effectiveness research: Relevance and applications to pharmacyGlen T Schumock, A Simon Pickard
Journal of Comparative Effectiveness Research|February 22, 2018
Comparative effectiveness and patient-centered outcomes research: enhancing uptake and use by patients, clinicians and payersGlen T Schumock, A Simon Pickard
Healthcare Financial Management : Journal of the Healthcare Financial Management Association|October 17, 2003
Expenditures for prescription drugs: too much or not enough?Glen T Schumock, Surrey M Walton
Archives of Internal Medicine|December 3, 2002
Aspirin use may change cost-effectiveness of COX-2 inhibitorsA Simon Pickard, Glen T Schumock
Pageof 14